局灶性癫痫的治疗:专利回顾。

IF 1.8 Q3 PHARMACOLOGY & PHARMACY
Pharmaceutical patent analyst Pub Date : 2021-05-01 Epub Date: 2021-06-02 DOI:10.4155/ppa-2021-0008
Slobodan M Janković, Nenad Marković, Tanja Luković
{"title":"局灶性癫痫的治疗:专利回顾。","authors":"Slobodan M Janković,&nbsp;Nenad Marković,&nbsp;Tanja Luković","doi":"10.4155/ppa-2021-0008","DOIUrl":null,"url":null,"abstract":"<p><p>Focal epilepsy is one of the most frequent specific type of epilepsies, with 30% treatment-resistant patients. There are several directions researchers can follow to improve existing treatment of focal epilepsy: synthesis of new compounds with anticonvulsant activity, repurposing drugs approved for other indications, finding drugs targeted to specific genetic and biochemical defects that underlie focal epilepsy syndromes, development of viral vectors for specific gene therapy, creation of devices and methods for suppression of seizures by electrostimulation and development of methods to increase safety of epilepsy surgery. Improvement of efficacy and safety of current therapies is necessary, as well as developing targeted treatment of genetic epilepsy syndromes that will not only suppress seizures, but stop further epileptogenesis.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 3","pages":"165-173"},"PeriodicalIF":1.8000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treating of focal epilepsy: a patent review.\",\"authors\":\"Slobodan M Janković,&nbsp;Nenad Marković,&nbsp;Tanja Luković\",\"doi\":\"10.4155/ppa-2021-0008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Focal epilepsy is one of the most frequent specific type of epilepsies, with 30% treatment-resistant patients. There are several directions researchers can follow to improve existing treatment of focal epilepsy: synthesis of new compounds with anticonvulsant activity, repurposing drugs approved for other indications, finding drugs targeted to specific genetic and biochemical defects that underlie focal epilepsy syndromes, development of viral vectors for specific gene therapy, creation of devices and methods for suppression of seizures by electrostimulation and development of methods to increase safety of epilepsy surgery. Improvement of efficacy and safety of current therapies is necessary, as well as developing targeted treatment of genetic epilepsy syndromes that will not only suppress seizures, but stop further epileptogenesis.</p>\",\"PeriodicalId\":20011,\"journal\":{\"name\":\"Pharmaceutical patent analyst\",\"volume\":\"10 3\",\"pages\":\"165-173\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical patent analyst\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4155/ppa-2021-0008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/6/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical patent analyst","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/ppa-2021-0008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

局灶性癫痫是最常见的癫痫类型之一,30%的患者对治疗有抵抗性。研究人员可以遵循以下几个方向来改善局灶性癫痫的现有治疗:合成具有抗惊厥活性的新化合物,重新利用已批准用于其他适应症的药物,寻找针对局灶性癫痫综合征的特定遗传和生化缺陷的药物,开发用于特定基因治疗的病毒载体,开发通过电刺激抑制癫痫发作的设备和方法,以及开发提高癫痫手术安全性的方法。提高现有治疗方法的有效性和安全性是必要的,同时开发针对遗传性癫痫综合征的靶向治疗方法,不仅可以抑制癫痫发作,还可以阻止进一步的癫痫发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treating of focal epilepsy: a patent review.

Focal epilepsy is one of the most frequent specific type of epilepsies, with 30% treatment-resistant patients. There are several directions researchers can follow to improve existing treatment of focal epilepsy: synthesis of new compounds with anticonvulsant activity, repurposing drugs approved for other indications, finding drugs targeted to specific genetic and biochemical defects that underlie focal epilepsy syndromes, development of viral vectors for specific gene therapy, creation of devices and methods for suppression of seizures by electrostimulation and development of methods to increase safety of epilepsy surgery. Improvement of efficacy and safety of current therapies is necessary, as well as developing targeted treatment of genetic epilepsy syndromes that will not only suppress seizures, but stop further epileptogenesis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmaceutical patent analyst
Pharmaceutical patent analyst PHARMACOLOGY & PHARMACY-
CiteScore
1.80
自引率
0.00%
发文量
22
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信